Trial Profile
A Phase 1b, Open-Label, Dose-Escalation Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Tivozanib (Primary)
- Indications Colorectal cancer; Gastrointestinal cancer
- Focus Adverse reactions
- 30 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Sep 2011 Planned end date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 22 Jan 2011 Results from this trial presented at the ASCO Gastrointestinal Cancers Symposium in January 2011.